Catalyst Pharmaceuticals Announces The Appointment Of Dr. Daniel Curran To Board Of Directors To Boost Strategic Growth

Catalyst Pharmaceuticals has announced the appointment of Dr. Daniel Curran to its Board of Directors. Dr. Curran is a highly experienced pharmaceutical executive with a career spanning over 25 years, covering a wide range of areas including corporate strategy, business development, project leadership, and drug development.

Since March 2024, Dr. Curran has been serving as the Managing Partner of Mountainfield Venture Partners, a company-creation firm focused on advancing early-stage biotech innovations. Alongside this role, he is also the Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage biotechnology company dedicated to developing and commercializing innovative therapies for autoimmune diseases.

Dr. Curran spent a significant part of his career at Takeda Pharmaceutical Company, where he held several leadership roles from 2008 to 2023. He most recently served as Senior Vice President and Head of the Rare Genetics and Hematology Therapeutic Area Unit from January 2019 to December 2023. Prior to his tenure at Takeda, he was Vice President of Corporate Development at Millennium Pharmaceuticals from 1999 to 2008. Earlier in his career, he held a business development role in the product planning and acquisition group at DuPont Merck Pharmaceuticals.

Patrick J. McEnany, Chairman of the Board of Catalyst, stated, "Dan brings an exceptional combination of strategic insight, rare disease expertise, and business development acumen, making him an outstanding addition to our Board. His leadership in advancing transformative therapies, paired with a proven history of delivering results across the full development continuum, will be instrumental as Catalyst continues to execute its disciplined growth strategy, which includes maximizing our current rare disease portfolio and acquiring strategically aligned assets.”

Dr. Curan also added, "I'm honored to join the Board of Catalyst and support its mission to deliver innovative therapies to patients with serious and underserved conditions. Catalyst has built a strong foundation through disciplined execution and strategic asset acquisition, and I look forward to contributing to the Company's continued growth and long-term value creation.”

In addition to his executive roles, Dr. Curran has also contributed to the biotech industry through board service. He previously served on the board of directors of Tome Biosciences, a private biotechnology company, and currently sits on the Board of Directors of Xilio Therapeutics, a publicly traded clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies. Dr. Curran holds a Doctor of Medicine degree from the University of Pennsylvania School of Medicine, an MBA from The Wharton School of the University of Pennsylvania, and a Bachelor of Science degree in Chemistry from King's College.